|
Abnormal localization of kidney
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormal nasal morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Absent speech
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acute lymphocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We show here that Ph-positive cell lines as well as primary cells derived from chronic myeloid leukemia (CML) in lymphoid blast crisis or from acute lymphoblastic leukemia (ALL) consistently express high levels of cyclin D2, whereas expression of this protein is low or absent in comparable Ph-negative lines and Ph-positive myeloid lines.
|
11691826 |
2001 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of core-binding factor acute myeloid leukemias.
|
27798625 |
2016 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of core-binding factor acute myeloid leukemias.
|
27798625 |
2016 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
Data from the Cancer Genome Atlas (TCGA) database indicated statistically significant negative correlation between PICOT and CCND2 in eight different human tumors where the highest correlation was in lung (p = 8.67E-10) and pancreatic (p = 1.06E-5) adenocarcinoma.
|
31527584 |
2019 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
Genomic DNA was extracted, quantitated, and evaluated with methylation-specific PCR for cyclin D2 in 8 adenocarcinoma cases.
|
26466823 |
2016 |
|
Adenocarcinoma
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
Methylation of cyclin D2 was identified in 65.1% (71 of 109) of primary pancreatic adenocarcinomas, in 50% (23 of 46) of IPMNs, and in 70% (7 of 10) of mucinous cystic neoplasms, but was detected infrequently in microdissected samples of normal pancreatic epithelia [7.7% (1 of 13)] and in pancreatic intraepithelial neoplasms [14.3% (2 of 14)].
|
12684418 |
2003 |
|
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
|
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |
|
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis.
|
23266556 |
2013 |
|
Adenocarcinoma of pancreas
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
We investigated the methylation of cyclin D2 in aging and pancreatic neoplastic development, and the utility of cyclin D2 methylation as a marker of pancreatic adenocarcinoma.
|
12684418 |
2003 |
|
Adenoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We show here that Ph-positive cell lines as well as primary cells derived from chronic myeloid leukemia (CML) in lymphoid blast crisis or from acute lymphoblastic leukemia (ALL) consistently express high levels of cyclin D2, whereas expression of this protein is low or absent in comparable Ph-negative lines and Ph-positive myeloid lines.
|
11691826 |
2001 |
|
Adult Anaplastic Astrocytoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Two glioblastomas and one anaplastic astrocytoma showed CCND2 gene amplification, but lacked significant overexpression of CCND2 transcripts.
|
10416984 |
1999 |
|
Adult Burkitt Lymphoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The predominant cyclin D2 expression in the LCLs and group III BLs correlated with an activated B-cell phenotype.
|
8959341 |
1996 |
|
Adult Burkitt Lymphoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The different levels of cyclin D2 transcripts in Burkitt's lymphoma cell lines expressing different subsets of EBV immortalizing genes suggest an involvement of EBNA-2 or EBNA-LP in cyclin D2 regulation.
|
8045261 |
1994 |
|
Adult Burkitt Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Thus, methylation appears to play a direct role in the regulation of the cyclin D2 locus in BL.
|
7529333 |
1995 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
|
17593082 |
2007 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
|
31568682 |
2020 |
|
Adult Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our results show that cyclin-D2 and D3 proteins are expressed in many more lymphoma subtypes than cyclin-D1.
|
20062012 |
2010 |
|
Adult Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
CCND2 was positive and restricted to the nuclei in all EBV(+) SCID mouse lymphoma lines, whereas it was limited to the cytoplasm in half of the EBV(-) counterparts.
|
11291051 |
2001 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on recent publications, we selected 10 genes that were frequently altered in medulloblastoma: CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 (now renamed as KMT2D).
|
26290144 |
2015 |